when will compounded semaglutide be unavailable FDA is moving to restrict mass-marketed GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified Compounding pharmacies to halt semaglutide

Users who track their weight loss progress often find that resolving constipation with proper fiber supplementation reveals weight loss that was previously hidden by retained stool

Long-term use of GLP-1 medications has been associated with sustained weight loss, improved glycemic control, and beneficial cardiovascular outcomes

However, tirzepatide was removed from the FDA drug shortage list, triggering restrictions on compounded versions

These are logical applications given the mechanisms involved, but both require further study

Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss